UTMB Research on Severe Asthma (UROSA) Study

Asthma Clinical Trial

— UROSA  

Official title:

UTMB Research on Severe Asthma (UROSA) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02264691
• Other study ID #: 08-128
• Status: Completed
• Phase: N/A
• First received: October 8, 2014
• Last updated: October 25, 2016
• Start date: March 2009
• Est. completion date: July 2016

Study information

• Verified date: October 2016
• Source: The University of Texas Medical Branch, Galveston
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

To identify and understand biologic aspects of severe asthma compared to subjects with mild to moderate asthma and subjects without asthma (normal or healthy volunteers).

Description:

It has been shown that severe asthma differs from milder asthma in its pathophysiology; in particular we are interested in examining why patients with severe asthma have disease that is resistant to corticosteroids. While we will be studying patients with severe asthma, we also need to study subjects to act as controls. To this end we will recruit subjects into the following groups: Normal volunteers; Mild asthmatics not taking inhaled corticosteroids; Mild to moderate asthmatics requiring and using inhaled corticosteroids and Severe asthmatics.

Subjects between the ages of 18 and 65 will be enrolled in this study. We aim to recruit enough subjects such that 120 male and female participants (30 in each of the above groups) will complete the bronchoscopy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• All participants must be in good general health (with exception to asthma). • Normal controls / healthy volunteers (NC) subjects with no past history of asthma or other lung disease. To determine this, subjects must have an FEV1 equal to or greater than 80% of predicted value and have a normal FEV1/FVC ratio.

Asthma subjects Eligible asthmatic participants must have a physician diagnosis of asthma for at least 1 year. Participants must either have historical evidence of reversibility of FEV1 of at least 12%, or demonstrate such a change during the study visits, or must have historical evidence of a PC20 for methacholine < 8mg/ml.

• Mild Asthma with no Corticosteroids (MANC) will be defined as control of asthma with short acting ß2-agonists or leukotrine antagonist or both, but not requiring inhaled corticosteroids.

• Mild to Moderate asthma (MMA) will be defined as control of asthma with an inhaled corticosteroid (less than or equal to 250 mcg daily inhaled fluticasone equivalent) in addition to the medications listed in the MANC group or long acting ß2-agonists.

• Severe asthma (SA) will be defined according to the ATS criteria for Refractory Asthma (10)

Exclusion Criteria:

• Exclusion criteria apply for all subjects:

• Current smoker, or former smoker with >10 pack years history or having quit within the past year

• Asthma exacerbation, requiring a new or increased dose of oral corticosteroids, within the past 30 days

• Pregnant or lactating female

• Significant/uncontrolled medical condition (uncontrolled diabetes, coronary artery disease, uncontrolled hypertension)

• Diagnosis of emphysema or other significant pulmonary disease

• If, in the opinion of the PI (WJC) the subject has co-morbid conditions that make them unsafe to undergo bronchoscopy, subjects will be given the choice to withdraw from the study or allowed to complete visits 1-3 only.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
United States	University of Texas Medical Branch	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluate patients with severe asthma	To evaluate patients with severe asthma and to establish the mechanisms by which the lack of response to treatment may occur.	7 Years	No